Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 13/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982210 | 0.88 | PDPK1 (0.78) | PDPK1MAPT | |
| SCHEMBL980502 | 0.88 | PDPK1 (0.78) | PDPK1MAPT | |
| SCHEMBL978868 | 0.86 | PDPK1 (1.00) | PDPK1MAPTSMN1; SMN2TP53 | |
| SCHEMBL981939 | 0.85 | PDPK1 (0.77) | PDPK1MAPTSMN1; SMN2TP53POLB | |
| SCHEMBL978943 | 0.84 | PDPK1 (0.85) | PDPK1MAPTSMN1; SMN2TP53 | |
| Ar-12 SCHEMBL570472 | 0.84 | PDPK1 (1.00) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| Ar-12 SCHEMBL30099806 | 0.84 | PDPK1 (1.00) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL5674265 | 0.81 | PDPK1 (1.00) | PDPK1 | |
| SCHEMBL12213581 | 0.81 | PDPK1 (0.73) | PDPK1 | |
| SCHEMBL13608762 | 0.81 | PDPK1 (0.81) | PDPK1MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9457031-B2 | Antibacterial protein kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2016-10-04 | — | — | US | disclosed |
| US-9457031-B2 | Antibacterial protein kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2016-10-04 | — | — | US | disclosed |
| US-9457031-B2 | Antibacterial protein kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2016-10-04 | — | — | US | disclosed |
| US-20150258100-A1 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2015-09-17 | — | — | US | disclosed |
| US-20150258100-A1 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2015-09-17 | — | — | US | disclosed |
| US-20150258100-A1 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258100-A1 | ANTIBACTERIAL PROTEIN KINASE INHIBITORS | DMPK, MYLK3, MYLK2 | PDPK1 110/4885MAPT 2537/4885SMN1; SMN2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.